Ernst Lengyel

Q: What Schools Are Affiliated With Ernst Lengyel

Ernst Lengyel is affiliated with the following schools: Northwestern University , University of Chicago, Semmelweis University, University of California, San Francisco

Ernst Lengyel's AcademicInfluence.com Rankings

Ernst Lengyel

Philosophy

#8643

World Rank

#12059

Historical Rank

Logic

#5669

World Rank

#7086

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Ernst Lengyel's Degrees

Doctorate Medicine Semmelweis University
PhD Molecular Biology Semmelweis University

Why Is Ernst Lengyel Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Ernst Robert Lengyel is an American gynecologic oncologist. Lengyel is the Arthur L. and Lee G. Herbst Professor of Obstetrics and Gynecology at the University of Chicago. Lengyel directs the Ovarian Cancer Research Laboratory, a translational research laboratory focused on understanding ovarian cancer metastasis and on developing and testing new treatments for ovarian cancer. In this role, Lengyel and his research team began to investigate the role of the fallopian tube in ovarian cancer as the cells more closely resemble those in the fallopian tube rather than the ovary.

(See a Problem?)

Ernst Lengyel's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. (2008) (2230)
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth (2011) (1638)
Ovarian cancer development and metastasis. (2010) (1331)
Whole–genome characterization of chemoresistant ovarian cancer (2015) (1175)
Rethinking ovarian cancer: recommendations for improving outcomes (2011) (1148)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
Adipose tissue and adipocytes support tumorigenesis and metastasis. (2013) (554)
Let-7 expression defines two differentiation stages of cancer (2007) (482)
m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer (2018) (464)
Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b (2000) (419)
Stimulation of 92-kDa Gelatinase B Promoter Activity by ras Is Mitogen-activated Protein Kinase Kinase 1-independent and Requires Multiple Transcription Factor Binding Sites Including Closely Spaced PEA3/ets and AP-1 Sequences (*) (1996) (375)
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. (2001) (358)
Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. (2008) (343)
The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. (2008) (340)
MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. (2012) (309)
Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. (2005) (278)
Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis (2018) (263)
C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu (2005) (261)
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. (2007) (253)
Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades (1997) (249)
Let-7 Prevents Early Cancer Progression by Suppressing Expression of the Embryonic Gene HMGA2 (2007) (248)
Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra‐cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum (2007) (241)
Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. (2018) (234)
CD95 promotes tumour growth (2011) (233)
Proteomics reveals NNMT as a master metabolic regulator of cancer associated fibroblasts (2019) (231)
Ligand independent activation of c-Met by fibronectin and α5β1-integrin regulates ovarian cancer invasion and metastasis (2010) (226)
Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. (2014) (220)
Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum (2019) (211)
Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation (2004) (188)
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. (2016) (173)
MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment (2015) (173)
Epithelial ovarian cancer experimental models (2014) (166)
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status (2016) (163)
Relationship of Type II Diabetes and Metformin Use to Ovarian Cancer Progression, Survival, and Chemosensitivity (2012) (157)
Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. (2019) (156)
CD95/Fas promotes tumour growth (2010) (156)
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. (2011) (145)
Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy (2015) (141)
Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. (2016) (137)
Let‐7 modulates acquired resistance of ovarian cancer to Taxanes via IMP‐1‐mediated stabilization of multidrug resistance 1 (2012) (134)
MMP-2 functions as an early response protein in ovarian cancer metastasis (2009) (127)
The urokinase plasminogen activator system as a novel target for tumour therapy (2000) (122)
Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. (2001) (115)
HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. (2012) (111)
Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. (2015) (105)
Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. (1996) (102)
Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis (2011) (97)
Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells (2016) (96)
Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. (1995) (94)
miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin α5 expression. (2013) (93)
Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer (2018) (91)
Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor* (1999) (90)
Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. (2009) (89)
Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance (2020) (83)
Thrombin Induces Tumor Invasion through the Induction and Association of Matrix Metalloproteinase-9 and β1-Integrin on the Cell Surface* (2008) (78)
Who are the long-term survivors of high grade serous ovarian cancer? (2018) (77)
Involvement of a Mitogen-activated Protein Kinase Signaling Pathway in the Regulation of Urokinase Promoter Activity by c-Ha-ras(*) (1995) (76)
Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade (1997) (75)
WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer (2014) (75)
Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment (2020) (75)
Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment (2015) (74)
Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis (2021) (74)
Integrin αvβ3/Vitronectin Interaction Affects Expression of the Urokinase System in Human Ovarian Cancer Cells* (2001) (73)
An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. (2010) (72)
Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis (2010) (71)
Tyrosine kinase mutations in human cancer. (2007) (68)
In vitro modulation of human melanoma cell invasion and proliferation by all-frans-retinoic acid (1998) (68)
The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma (2015) (67)
Deep Visual Proteomics defines single-cell identity and heterogeneity (2022) (67)
The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. (2011) (66)
Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis (2015) (62)
{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. (2009) (62)
Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor–Engineered T Cells for Ovarian Cancer (2018) (61)
Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. (2009) (59)
Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. (2014) (57)
Regulation of urokinase‐type plasminogen activator expression by an ERK1‐dependent signaling pathway in a squamous cell carcinoma cell line (1996) (56)
Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform (2016) (53)
Differential expression of c‐Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue (2007) (53)
β3A-Integrin Downregulates the Urokinase-Type Plasminogen Activator Receptor (u-PAR) through aPEA3/ets Transcriptional Silencing Element in the u-PAR Promoter (2001) (53)
Old drug, new trick: repurposing metformin for gynecologic cancers? (2014) (52)
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. (2015) (50)
The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. (2010) (47)
Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. (2008) (46)
A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings (2009) (46)
A streamlined mass spectrometry–based proteomics workflow for large‐scale FFPE tissue analysis (2020) (45)
RADAR: differential analysis of MeRIP-seq data with a random effect model (2019) (45)
Statin Therapy Is Associated with Improved Survival in Patients with Non-Serous-Papillary Epithelial Ovarian Cancer: A Retrospective Cohort Analysis (2014) (43)
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer (2019) (42)
Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. (2001) (41)
Three-dimensional modeling of ovarian cancer. (2014) (40)
PDGFR-α as a potential therapeutic target in uterine sarcomas (2007) (39)
Unsaturated Fatty Acids Maintain Cancer Cell Stemness. (2017) (39)
Src Induces Urokinase Receptor Gene Expression and Invasion/Intravasation via Activator Protein-1/p-c-Jun in Colorectal Cancer (2007) (37)
UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. (1999) (36)
Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake (2019) (36)
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer (2015) (35)
A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. (2019) (35)
A streamlined mass spectrometry-based proteomics workflow for large scale FFPE tissue analysis (2019) (34)
Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake (2019) (33)
A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. (2016) (33)
Urokinase Plasminogen Activator System–Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapy (2013) (31)
Gastrin Induces Expression and Promoter Activity of the Vesicular Monoamine Transporter Subtype 2. (2001) (30)
Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. (1995) (29)
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference (2019) (29)
Patterns and utility of routine surveillance in high grade endometrial cancer. (2015) (28)
Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. (1995) (27)
Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2α-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers (2005) (27)
New Roles for Glycogen in Tumor Progression. (2019) (27)
An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells (2017) (27)
PDGFR-alpha as a potential therapeutic target in uterine sarcomas. (2007) (26)
Change in Health-Related Socioeconomic Risk Factors and Mental Health During the Early Phase of the COVID-19 Pandemic: A National Survey of U.S. Women. (2021) (26)
Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. (2003) (25)
High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. (2017) (25)
Downregulation of a Mitogen‐Activated Protein Kinase Signaling Pathway in the Placentas of Women With Preeclampsia (2000) (25)
The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial–stromal interactions (2010) (23)
Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. (2019) (23)
A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth (2017) (22)
Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. (2012) (21)
Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. (2019) (19)
The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. (2019) (19)
FOXL2 and SOX9 Distinguish the Lineage of the Sex Cord–Stromal Cells in Gonadoblastomas (2011) (19)
Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. (2009) (19)
Adipose tissue and adipocytes supports tumorigenesis and metastasis (2013) (19)
Deconstructing tumor heterogeneity: the stromal perspective (2020) (18)
Effects of Oral Contraceptives or a Gonadotropin-Releasing Hormone Agonist on Ovarian Carcinogenesis in Genetically Engineered Mice (2009) (18)
CD95 promotes tumour growth (2011) (18)
Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention (2017) (17)
Old Drug, New Trick: Repurposing Metformin for Gynecologic Cancers? (2015) (17)
The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. (2018) (16)
Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. (2009) (16)
Role of β3-endonexin in the regulation of NF-κB-dependent expression of urokinase-type plasminogen activator receptor (2002) (16)
Corrigendum: Whole–genome characterization of chemoresistant ovarian cancer (2015) (16)
Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. (2008) (16)
Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis (2019) (14)
3 -Integrin Expression on Tumor Cells Inhibits Tumor Progression, Reduces Metastasis, and Is Associated with a Favorable Prognosis in Patients with Ovarian Cancer (2009) (13)
Resilience: a mediator of the negative effects of pandemic-related stress on women’s mental health in the USA (2021) (13)
Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6 (2019) (12)
The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. (2011) (12)
Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. (2015) (12)
The effects of 17β-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. (2012) (11)
Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. (2004) (11)
Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. (2013) (10)
The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer (2021) (10)
Transverse Transperineal Repair of a Pessary-induced Mid-rectovaginal Fistula (2008) (10)
The Natural Product β-Escin Targets Cancer and Stromal Cells of the Tumor Microenvironment to Inhibit Ovarian Cancer Metastasis (2021) (9)
Resilience in the Face of Pandemic: The Impact of COVID-19 on the Psychologic Morbidity and Health-Related Quality of Life Among Women With Ovarian Cancer (2022) (9)
Keratin expression reveals mosaic differentiation in vaginal epithelium. (1993) (9)
Neoadjuvant Chemotherapy Induces Genomic and Transcriptomic Changes in Ovarian Cancer (2021) (8)
Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. (2017) (8)
The adipocyte microenvironment and cancer (2022) (7)
Supplementary Methods for MicroRNAs Reprogram Normal Fibroblasts into CancerAssociated Fibroblasts in Ovarian Cancer (2012) (7)
Ras regulation of urokinase-type plasminogen activator. (2001) (7)
Are We Ready for Hyperthermic Intraperitoneal Chemotherapy in the Upfront Treatment of Ovarian Cancer? (2020) (6)
The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment (2021) (6)
Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation (2019) (5)
[The clinical importance of keratin 18 in breast cancer]. (1995) (4)
Complete Response in a Patient With Chemorefractory EGFR-Amplified, PD-L1-Positive Metastatic Gastric Cancer Treated By Dual Anti-EGFR and Anti-PD-1 Monoclonal Antibody Therapy. (2020) (4)
Isolation and characterization of Rac1 pseudogenes (ψ1Rac1–ψ4Rac1) in the human genome (2004) (3)
Erratum: CD95 promotes tumour growth (Nature (2010) 465 (492-496)) (2011) (3)
Abstract 1481: microRNA mediated reprograming of fibroblasts into cancer associated fibroblasts in ovarian cancer (2012) (3)
Acute inflammatory reaction following placement of sodium hyaluronate-carboxymethylcellulose barrier in a young woman undergoing gynecologic surgery: a case report. (2011) (3)
Erratum: Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy (2016) (3)
519 POSTER A phase 2, single-arm study of volociximab (an anti-a5b1 integrin antibody) monotherapy in patients with platinum-resistant advanced epithelial ovarian cancer or primary peritoneal cancer (2008) (3)
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. (2021) (3)
Gastrin induces expression and promoter activity of the vesicular monoamine transporter subtype 2. (2001) (3)
Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. (2020) (3)
Integrin a v b 3 /Vitronectin Interaction Affects Expression of the Urokinase System in Human Ovarian Cancer Cells* (2001) (3)
High glucocorticoid receptor expression in the sarcomatous versus carcinomatous elements of Mullerian carcinosarcomas (2022) (2)
Profiling the metabolomic composition of the ovarian cancer secretome and ovarian cancer-induced metabolomic changes in mesothelial cells (2019) (2)
Advancing metformin as a metabolic therapeutic for ovarian cancer: Testing in non-diabetic patient-derived xenograft avatars (2015) (2)
Nicotinamide N-methyltransferase metabolically reprograms the stroma to promote ovarian cancer metastasis. (2018) (2)
Ovarian cancer treatment in black and white women: A comparison of clinico-pathologic factors and outcome (2008) (1)
Treatment with an uPAR (ATN 658) antibody inhibits ovarian cancer metastasis. (2007) (1)
Human Fallopian Tube and Ovary Dissociation for Single Cell RNA-Seq v1 (2020) (1)
C-Met overexpression identifies breast cancer patients with poor clinical outcome independent of Her2/neu. (2003) (1)
RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. (2001) (1)
Ovarian Masses: The Value of Acoustic Shadowing on Ultrasound Examination (2022) (1)
Abstract 4416: Reversal of chemoresistance in ovarian cancer cells by the liposomal co-delivery of MDR inhibitors and paclitaxel (2015) (1)
Erratum: CD95 promotes tumour growth (Nature (2010) 465 (492-496) DOI: 10.1038/nature09075) (2012) (1)
P3. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2α-related factor binding to different regions of the urokinase receptor (u-PAR) gene in resected colorectal cancers (2006) (1)
Adipocytes reprogram glucose metabolism in cancer cells promoting metastasis (2022) (1)
Abstract 3062: Metformin inhibits TGFβ-induced stromal ECM remodeling to impede invasion in ovarian cancer (2017) (1)
The future starts here! (2006) (1)
The glycoprotein CD147 defines miRNA‐enriched extracellular vesicles that derive from cancer cells (2023) (1)
Abstract AS23: Microenvironment mediated downregulation of miR-193b promotes ovarian cancer metastasis (2015) (1)
Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. (2013) (1)
First clinical evidence of a combined AP-2/Sp1 promoter motif as a tumor-specific activator of urokinase-receptor (u-PAR) expression in resected gastrointestinal cancers (2001) (1)
RADAR: differential analysis of MeRIP-seq data with a random effect model (2019) (1)
Transcriptional Control of Proteases (2002) (1)
Cancer Therapy : Preclinical Foretinib ( GSK 1363089 ) , an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2 , Blocks Proliferation , Induces Anoikis , and Impairs Ovarian Cancer Metastasis (2011) (1)
The balance between toxic versus nontoxic microRNAs determines platinum sensitivity in ovarian cancer (2021) (1)
Abstract 2611: The developmental patterning geneHOXA9promotes ovarian cancer growth via paracrine effects on mesenchymal stem cells and peritoneal fibroblasts. (2013) (0)
Focused Plenary I - Pre-Clinical Discovery (2015) (0)
Abstract NT-097: QUANTITATIVE HIGH-THROUGHPUT SCREENING USING AN ORGANOTYPIC MODEL IDENTIFIES TWO KINASE INHIBITORS THAT INHIBIT OVARIAN CANCER METASTASIS (2019) (0)
Abstract 5185: Ovarian cancer cells induce fibronectin production in the peritoneal microenvironment through a TGFβRI-dependent mechanism which promotes the early steps of metastasis (2012) (0)
Abstract IA06: Stromal regulation of metastasis (2018) (0)
A prospective study to evaluate diffusion weighted MRI (DW-MRI) imaging in the detection of peritoneal carcinomatosis (2013) (0)
Corrigendum: CD95 promotes tumour growth (2012) (0)
Cancer Therapy: Preclinical Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis (2011) (0)
Abstract POSTER-CTRL-1217: Human placental lactogen-functionalized bimodal imaging probe for human ovarian cancer detection (2015) (0)
Utility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients (2012) (0)
Abstract 2331: One of the first steps of metastasis is remodeling of the extracellular matrix microenvironment (2010) (0)
A Special Key for Unlocking the Door to Targeted Therapies of Breast Cancer (2008) (0)
Regulation of ovarian cancer metastatic colonization by MIR-193B (2013) (0)
A prospective study to evaluate diffusion weighted MRI imaging in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies (2015) (0)
Abstract 1870: Omental adipocytes promote overexpression of CD36 in ovarian cancer cells and enhance tumorigenicity. (2013) (0)
Heterogeneity of operative approach in long-term survivors of high-grade serous carcinoma (2018) (0)
Abstract 48: Activation of c-Met receptor signaling by carcinoma-associated fibroblasts in the tumor microenvironment (2012) (0)
Metabolic reprogramming of the stromal epigenome in ovarian cancer metastasis (2019) (0)
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts (2019) (0)
Abstract POSTER-TECH-1123: Advancing metformin as therapeutic for ovarian cancer: metabolomic profiling of mouse ovarian tumors identifies metformin-induced global metabolic changes (2015) (0)
Abstract 6068: Methylomic, transcriptomic and immune profiles of high grade serous ovarian cancer among Black and non-Hispanic White women (2023) (0)
Fatty acid binding protein 4 is indispensable for ovarian cancer metastasis. (2018) (0)
A molecular atlas of the human postmenopausal fallopian tube and ovary from single-cell RNA and ATAC sequencing (2022) (0)
Proteomics identifies CT45 as a mediator of chemosensitivity and immunotherapy target in ovarian cancer. (2018) (0)
Abstract B39: Identification and targeting mediators of chemoresistance using the patient-derived xenograft model of ovarian cancer (2016) (0)
Biochi ~ ic ~ a et Biophysica A ~ ta Stimulation of urokinase expression by TNF-a requires the activation of binding sites for the AP-1 and PEA 3 transcription factors (2003) (0)
Abstract 4462: Immunoregulatory effects of NNMT-expressing cancer-associated fibroblasts (2023) (0)
Abstract PR11: Ovarian cancer cells activate the mesothelium in the peritoneal microenvironment promoting fibronectin production and the early steps of metastasis (2013) (0)
MicroRNA 206 is associated with longer overall survival and platinum sensitivity in serous epithelial ovarian cancer (2014) (0)
Modulation of lipid metabolism in interacting visceral adipocytes and ovarian cancer cells (2011) (0)
Germline mutations in Black women with ovarian, fallopian tube and primary peritoneal carcinomas (2022) (0)
UVB induces the transcription of urokinase receptor in A431 cells (1998) (0)
Abstract 5474: Activity of the S1P pathway promotes ovarian cancer and serves as a novel metabolic target of metformin (2018) (0)
m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer (2018) (0)
Small-Molecule Inhibitor of c-Met , PF-2341066 , Reduces Tumor Burden and Metastasis in a Preclinical Model of Ovarian Cancer Metastasis 1 (2014) (0)
Abstract POSTER-THER-1440: Targeted delivery of doxorubicin loaded nanobins to ovarian cancer cells through the urokinase plasminogen activator system (2015) (0)
Abstract 6782: Spatial transcriptomics of serous tubal intraepithelial carcinoma and its putative precursor lesions (2023) (0)
Abstract A103: The effect of 17β-estradiol on ovarian carcinogenesis in vitro and in a genetic mouse model (2010) (0)
Analysis of molecular profile complexities for immunotherapy decision support (2019) (0)
Erratum: CD95 promotes tumour growth (Nature (2011) 471 (254) DOI: 10.1038/nature09897) (2011) (0)
Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment (2022) (0)
Cancer-associated mesothelial cell–derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis (2023) (0)
Locoregional Failure In High-risk Endometrial Cancer And The Role Of Whole Pelvis External Beam RT (2011) (0)
Abstract IA30: Metabolic symbiosis: The contribution of adipocytes to visceral metastasis (2013) (0)
Understanding Long-Term Survival of Patients with Ovarian Cancer-The Tumor Microenvironment Comes to the Forefront. (2023) (0)
Abstract 1544: Identification of microRNA which regulates peritoneal dissemination of ovarian cancer (2011) (0)
Polycomb fusion proteins in endometrial stromal sarcomas (2018) (0)
Sarcoma regimens for gynecologic carcinosarcoma: Is there a benefit? (186) (2022) (0)
Abstract A15: Fatty acid binding protein 4 is indispensable for ovarian cancer metastasis (2018) (0)
An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells (2017) (0)
Reversal of Chemoresistance in Ovarian Cancer by Co‐Delivery of MDR Inhibitors and Paclitaxel Using a Targeted Liposomal Platform (2015) (0)
Abstract B32: The role of the glucocorticoid receptor (GR) in inhibiting chemotherapy-induced apoptosis in high-grade serous ovarian carcinoma (HGS-OvCa) (2013) (0)
Early postoperative increases in platelet count is associated with trend towards improved survival in high grade serous ovarian cancer (2019) (0)
Abstract TMEM-118: ROLES OF T-LAK CELL-ORIGINATED KINASE (TOPK) AND THE MICROENVIRONMENT IN DRIVING OVARIAN CANCER PROGRESSION (2017) (0)
Abstract LB-341: CD95/FAS promotes tumorigenesis (2010) (0)
P4. Tumor suppressor Pdcd4 inhibits invasion and regulates urokinase-receptor (u-PAR) gene expression via Sp-transcription factors (2006) (0)
Abstract A28: Beta-escin inhibits ovarian cancer metastasis by targeting the tumor microenvironment (2018) (0)
Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome. (2004) (0)
Abstract A68: Sphingosine kinase 1 as a mediator and predictor of metformin's protective effect in ovarian cancer. (2016) (0)
Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference (2019) (0)
Identifying the microrna expression signature associated with chemoresistance in ovarian cancer (2013) (0)
Ovarian cancer patients treated with intraperitoneal/intravenous chemotherapy do not experience increased toxicity at recurrence (2016) (0)
Β3-Integrin expression reduces ovarian cancer proliferation and metastasis (2007) (0)
2 THREE-DIMENSIONAL CULTURE MODELS OF OVARIAN CANCER TO RECAPITULATE THE TUMOR MICROENVIRONMENT (2014) (0)
Care of Transgender Persons. (2020) (0)
Diverse indications for risk-reducing salpingo-oophorectomy: Experience from a tertiary care center (2018) (0)
Neoadjuvant treatment as a window to chemotherapy driven alterations to the genome and transcriptome of high-grade serous ovarian cancer (2021) (0)
Predictors of Early Recurrence in Advanced Stage, Optimally Debulked Ovarian Cancers (2016) (0)
Abstract POSTER-BIOL-1305: Lovastatin decreases macrophage IL-6 and CXCL1 production in an ovarian tam-like model reducing ovarian cancer cell invasion (2015) (0)
Abstract 3655: Exploring the role of FasL in the ovarian cancer tumor microenvironment (2023) (0)
Fibroblasts Mobilize Tumo r Cell Glycogen to Promote Proliferation and Metastasis Graphical Abstract Highlights (2018) (0)
Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6 (2019) (0)
6mer Seed Toxicity and Platinum Resistance in Ovarian Cancer (2021) (0)
Abstract 5899: Compartment-resolved proteomics reveal NNMT as a master metabolic regulator of cancer associated fibroblasts (2017) (0)
Metformin: A novel agent for ovarian cancer prevention and adjuvant treatment (2012) (0)
Healthy food for trainees: a call to action (2020) (0)
Introducing standardized medical procedure and dynamic decision support program in precision oncology for the community of practice (2019) (0)
Abstract 2885: Urokinase plasminogen activator system targeted delivery of arsenic trioxide loaded nanobins as a novel ovarian cancer therapeutic (2012) (0)
Development of an organotypic peritoneal 3D culture to study peritoneal attachment of ovarian cancer cells. (2006) (0)
Subsequent chemotherapy is well tolerated in patients who underwent primary adjuvant intraperitoneal chemotherapy for ovarian, fallopian and primary peritoneal cancers (2015) (0)
The evaluation of norethindrone, ethinyl estradiol and a GnRh agonist as chemoprevention of ovarian cancer using a newly developed genetically engineered mouse model of ovarian cancer. (2007) (0)
Effective screening of neoantigen-specific cytotoxic t cells. (2018) (0)
Molecular cloning, expression and promoter analysis of the vesicular monoamine transporter subtype 2 (VMAT2) in human and rat gastric enterochromaffin-like (ECL) cells (1998) (0)

This paper list is powered by the following services:

Other Resources About Ernst Lengyel

en.wikipedia.org

What Schools Are Affiliated With Ernst Lengyel?

Ernst Lengyel is affiliated with the following schools:

Ernst Lengyel's Academic­Influence.com Rankings